Simon R - Search Results

1

Accelerated titration designs for phase I clinical trials in oncology.

Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Simon R, et al. J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47. doi: 10.1093/jnci/89.15.1138. J Natl Cancer Inst. 1997. PMID: 9262252

2

Application of molecular profiling in clinical trials for advanced metastatic cancers.

Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH. Kummar S, et al. J Natl Cancer Inst. 2015 Feb 6;107(4):djv003. doi: 10.1093/jnci/djv003. Print 2015 Apr. J Natl Cancer Inst. 2015. PMID: 25663694 Free PMC article.

3

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

Jiang W, Freidlin B, Simon R. Jiang W, et al. Among authors: simon r. J Natl Cancer Inst. 2007 Jul 4;99(13):1036-43. doi: 10.1093/jnci/djm022. Epub 2007 Jun 27. J Natl Cancer Inst. 2007. PMID: 17596577 Clinical Trial.

4

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.

Freidlin B, Simon R. Freidlin B, et al. Among authors: simon r. Clin Cancer Res. 2005 Nov 1;11(21):7872-8. doi: 10.1158/1078-0432.CCR-05-0605. Clin Cancer Res. 2005. PMID: 16278411

5

Trends in reported incidence of primary malignant brain tumors in children in the United States.

Smith MA, Freidlin B, Ries LA, Simon R. Smith MA, et al. Among authors: simon r. J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77. doi: 10.1093/jnci/90.17.1269. J Natl Cancer Inst. 1998. PMID: 9731733

6

Clinical trial designs for cytostatic agents: are new approaches needed?

Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Korn EL, et al. Among authors: simon r. J Clin Oncol. 2001 Jan 1;19(1):265-72. doi: 10.1200/JCO.2001.19.1.265. J Clin Oncol. 2001. PMID: 11134222 Review.

7

The cross-validated adaptive signature design.

Freidlin B, Jiang W, Simon R. Freidlin B, et al. Among authors: simon r. Clin Cancer Res. 2010 Jan 15;16(2):691-8. doi: 10.1158/1078-0432.CCR-09-1357. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068112

8

Evaluation of randomized discontinuation design.

Freidlin B, Simon R. Freidlin B, et al. Among authors: simon r. J Clin Oncol. 2005 Aug 1;23(22):5094-8. doi: 10.1200/JCO.2005.02.520. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983399

9

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.

Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Smith MA, et al. Among authors: simon r. J Clin Oncol. 1997 Jul;15(7):2736-43. doi: 10.1200/JCO.1997.15.7.2736. J Clin Oncol. 1997. PMID: 9215848

10

A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.

Chen TT, Chute JP, Feigal E, Johnson BE, Simon R. Chen TT, et al. Among authors: simon r. J Natl Cancer Inst. 2000 Oct 4;92(19):1601-7. doi: 10.1093/jnci/92.19.1601. J Natl Cancer Inst. 2000. PMID: 11018096

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,201 results

Search Page

Filters